Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that a Meeting of the Board of Directors of the Company will be held on Thursday, November 9, 2023, to consider and approve the following: Standalone & Consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2023 and payment of Interim Dividend, if any, for the financial year 2023-24. Further to its letter dated September 27, 2023, informing about the closure of Trading Window of the Company from October 1, 2023, until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2023, the company has informed that the Trading Window will remain closed up to November 11, 2023, and shall be re-opened on November 12, 2023.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: